# Efficacy and Safety of Sintilimab With or Without Radiotherapy in Patients With Recurrent or IV NSCLC (EGFR -, ALK -) After Failure of Platinum-based Chemotherapy: A Randomized,Open Labled, Phase II Clinical Study

> **NCT04513301** · PHASE2 · UNKNOWN · sponsor: **Shanghai Cancer Hospital, China** · enrollment: 70 (estimated)

## Conditions studied

- Lung Neoplasms

## Interventions

- **DRUG:** Sintilimab
- **RADIATION:** Radiotherapy

## Key facts

- **NCT ID:** NCT04513301
- **Lead sponsor:** Shanghai Cancer Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-01-01
- **Primary completion:** 2022-08-01
- **Final completion:** 2022-12-01
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2020-08-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04513301

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04513301, "Efficacy and Safety of Sintilimab With or Without Radiotherapy in Patients With Recurrent or IV NSCLC (EGFR -, ALK -) After Failure of Platinum-based Chemotherapy: A Randomized,Open Labled, Phase II Clinical Study". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04513301. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*